Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Rhea-AI Summary
Belite Bio (NASDAQ: BLTE), a clinical-stage drug developer targeting degenerative retinal diseases with significant unmet medical needs, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026, at 4:00 pm ET.
The presentation webcast and 90-day replay will be available in the Events section of Belite Bio’s investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction – BLTE
In the Jun 2 session, BLTE declined 8.21%, reflecting a notable negative market reaction. Argus tracked a trough of -6.6% from its starting point during tracking. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 20 | Earnings and update | Positive | +3.0% | Q1 2026 results plus NDA progress and commercialization hiring details. |
| May 18 | Regulatory designation | Positive | -2.2% | Swiss orphan status and Phase 3 success metrics for tinlarebant. |
| May 15 | Conference presentation | Positive | -4.6% | Retina China 2026 oral presentation of DRAGON topline data. |
| May 13 | Earnings webcast notice | Neutral | -2.3% | Scheduling Q1 2026 results webcast and business update call. |
| Apr 27 | Conference presentation | Positive | +1.1% | Retinal summit talk on DRAGON topline efficacy and safety results. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows mixed reactions: positive clinical and regulatory updates sometimes met with selling, while earnings and presentation-related news have drawn both buying and selling, indicating inconsistent news-to-price alignment.
Over the last few months, Belite Bio has progressed tinlarebant with repeated Phase 3 DRAGON topline presentations and a rolling NDA submission to the FDA, while also reporting Q1 2026 financials with commercialization preparation underway. News such as Swiss orphan drug status and conference presentations generally highlighted a 35.7% lesion reduction and supportive safety, yet share reactions alternated between gains and pullbacks. Today’s Goldman Sachs conference appearance fits the pattern of ongoing investor outreach following these key milestones.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 4:00 pm ET.
Webcast Link Instructions
Webcasts of the presentations can be accessed under "Events" in the investor relations section of the Belite Bio website at: https://investors.belitebio.com/presentations-events/events. The replays will be archived for 90 days following the presentation date.
About Belite Bio
Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical need, such as Stargardt disease type 1 (STGD1) and geographic atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite Bio’s lead candidate, tinlarebant, is an oral therapy intended to reduce the accumulation of bisretinoid toxins in the eye. The Company has completed a Phase 3 trial (DRAGON) in adolescent and adult subjects with STGD1, which met its primary endpoint, and the drug is currently being evaluated in a Phase 2/3 trial (DRAGON II) in adolescent and adult subjects with STGD1 and a Phase 3 trial (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook, or visit us at www.belitebio.com.
Media and Investor Relations Contacts:
Jennifer Wu / ir@belitebio.com
Argot Partners / belite@argotpartners.com
